By Benjamin Chiou
Date: Tuesday 24 Feb 2026
(Sharecast News) - Danish pharma giant Novo Nordisk is to halve the US price of obesity drug Wegovy and slash the price of diabetes treatment Ozempic from next year as competition ramps up with rival drugmaker Eli Lilly.
| Currency | US Dollars |
| Share Price | $ 1,028.83 |
| Change Today | $ -13.32 |
| % Change | -1.28 % |
| 52 Week High | $1,109.94 |
| 52 Week Low | $625.65 |
| Volume | 2,481,897 |
| Shares Issued | 944.80m |
| Market Cap | $972,039m |
| Beta | 0.01 |
| RiskGrade | 179 |
| Strong Buy | 12 |
| Buy | 12 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

| Time | Volume / Share Price |
| 16:00 | 344,442 @ $1,028.83 |
| 16:00 | 1,040 @ $1,029.53 |
| 15:59 | 800 @ $1,029.37 |
| 15:59 | 200 @ $1,029.37 |
| 15:59 | 240 @ $1,029.37 |
You are here: research